Get access

Canine ocular tumors following ciliary body ablation with intravitreal gentamicin

Authors

  • Felicia D. Duke,

    1. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive West, Madison, WI 53706, USA
    Search for more papers by this author
  • Travis D. Strong,

    1. School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive West, Madison, WI 53706, USA
    Search for more papers by this author
  • Ellison Bentley,

    1. Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, 2015 Linden Drive West, Madison WI 53706, USA
    Search for more papers by this author
  • Richard R. Dubielzig

    1. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive West, Madison, WI 53706, USA
    Search for more papers by this author

Address communications to:
F. D. Duke
Tel.: 608-263-4958
Fax: 608-262-9150
e-mail: duke@dvm.com

Abstract

Iridociliary tumors are the second most common primary ocular tumor in dogs and are usually benign. A review of the Comparative Ocular Pathology Laboratory of Wisconsin (COPLOW) database in 2009 suggested a potential correlation between malignant iridociliary epithelial tumors and ciliary body ablation by intravitreal gentamicin injection for the treatment of glaucoma. The purpose of this case series was to determine whether there is evidence of such a correlation in the COPLOW collection. Mining of the COPLOW database revealed that a significant number (39.5%) of canine globes with a history of ciliary body ablation were subsequently diagnosed with primary ocular tumors at enucleation, most commonly iridociliary epithelial tumors and melanocytic tumors. It is possible that neoplasia was present but unrecognized at the time of ciliary body ablation. These tumors had a higher than expected incidence of malignancy. These cases underscore the importance of reserving ciliary body ablation with gentamicin for disease-free eyes.

Get access to the full text of this article

Ancillary